EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER plus breast cancer and endometroid endometrial cancer - Lim, E; Beeram, M; Prawira, A (Cancer Res, 2021)